[Bionaut Labs in PR Newswire] FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients

First-in-class Bionaut™ treatment modality uses remote-controlled microscale robots to deliver biologics, nucleic acids, small molecule, gene or cellular therapies locally to targeted brain disease areas.

Read more here.